ISRIB Promotes Aggregation of TIA-1 by Modulating Its Phase Separation in Vitro.

Stress granules function as non-membranous compartments that assemble through the liquid-liquid phase separation (LLPS) of various ribonucleoproteins and genetic material during cellular distress. Prior research has shown that T-cell intracellular antigen-1 (TIA-1) serves as a foundational component for these assemblies, utilizing its low-complexity domain to drive the nucleation process. The integrated stress response inhibitor (ISRIB) represents a potent pharmacological tool designed to restore protein synthesis by targeting the eukaryotic initiation factor 2B complex. While this small molecule demonstrates significant promise in mitigating cognitive decline and neurodegeneration, its direct interaction with the structural proteins of stress granules remains poorly defined. The physical transition from functional liquid droplets to pathological solid aggregates is a hallmark of several proteinopathies, yet the influence of exogenous inhibitors on this transition is unclear. Scientists have long debated whether modulating the stress response pathway could inadvertently trigger the misfolding of RNA-binding proteins. This absence of evidence motivated an investigation into how the integrated stress response inhibitor influences the condensation and fibrillization of T-cell intracellular antigen-1.

This study evaluates the direct biochemical impact of the integrated stress response inhibitor (ISRIB) on the phase behavior and structural stability of the T-cell intracellular antigen-1 (TIA-1) protein. Researchers sought to determine whether this small molecule acts as a modulator of the liquid-to-solid transition within purified protein systems. The investigation specifically targets the low-complexity domain of the ribonucleoprotein to understand the molecular drivers of condensation. Another objective involves assessing how the presence of ribonucleic acid (RNA) molecules influences the interaction between the inhibitor and the protein scaffold. The team aimed to clarify if cellular environments, represented by complex lysates, alter the aggregation kinetics observed in simplified in vitro models. By characterizing these interactions, the study provides a mechanistic basis for understanding potential off-target effects of stress response modulation. These goals were established to ensure that the therapeutic benefits of the inhibitor do not come at the cost of proteostatic integrity.

The experimental design utilized purified recombinant T-cell intracellular antigen-1 (TIA-1) proteins to observe liquid-liquid phase separation (LLPS) under controlled buffer conditions. Scientists employed in vitro phase separation assays to monitor the formation of droplets following the addition of varying concentrations of the integrated stress response inhibitor (ISRIB). Aggregation kinetics were quantified using specialized imaging techniques and biochemical markers to track the progression from liquid condensates to insoluble protein clusters. The researchers introduced exogenous ribonucleic acid (RNA) into the reaction mixtures to simulate the natural composition of cellular stress granules. Comparative experiments were conducted using whole-cell lysates to provide a more physiologically relevant context for the observed protein behaviors. Statistical analysis of droplet size and frequency allowed for a precise determination of how the small molecule shifts the saturation concentration of the protein. These rigorous protocols ensured that the observed effects were attributable to the direct interaction between the small molecule and the protein of interest.

The integrated stress response inhibitor (ISRIB) significantly enhances the liquid-liquid phase separation (LLPS) of T-cell intracellular antigen-1 (TIA-1), leading to increased droplet formation in vitro. Exposure to this small molecule accelerates the transition of these liquid droplets into stable, solid-like aggregates over time. The presence of ribonucleic acid (RNA) effectively mitigates the pro-aggregatory effects of the inhibitor, suggesting a competitive or stabilizing interaction. Experiments involving cell lysates demonstrated a similar protective effect, where the complex environment prevented the rapid formation of insoluble protein structures. Data indicate that the low-complexity domain of the protein is the primary site of modulation by the integrated stress response inhibitor. The study confirms that the physical properties of these biomolecular condensates are highly sensitive to the ratio of protein, RNA, and pharmacological agents. These results provide clear evidence that the inhibitor can act as a molecular glue for specific stress-associated proteins.

These findings reveal that the integrated stress response inhibitor (ISRIB) possesses the capacity to alter the material state of stress granule proteins directly. The observation that ribonucleic acid (RNA) binding serves as a protective mechanism highlights the importance of the cellular context when evaluating therapeutic molecules. Clinicians and researchers must consider how these structural changes might influence the long-term safety of drugs targeting the integrated stress response. Future investigations should focus on whether these in vitro aggregation events translate to pathological inclusions in living systems. The study establishes a new framework for assessing the impact of small molecules on the dynamics of non-membranous organelles. Understanding these RNA-dependent interactions is essential for refining the application of inhibitors in neurodegenerative disease contexts. These insights suggest that the therapeutic window for such compounds may depend heavily on the intracellular concentration of available RNA.